PhaseBio Pharmaceuticals Debt/Assets

Debt/Assets of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Assets growth rates and interactive chart.


Highlights and Quick Summary

  • Debt/Assets for the quarter ending June 29, 2021 was 11.17% (a -11.28% decrease compared to previous quarter)
  • Year-over-year quarterly Debt/Assets decreased by -58.26%
  • Annual Debt/Assets for 2020 was 28.07% (a 40.56% increase from previous year)
  • Annual Debt/Assets for 2019 was 19.97% (a 67.82% increase from previous year)
  • Annual Debt/Assets for 2018 was 11.9% (a -89.16% decrease from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Assets of PhaseBio Pharmaceuticals

Most recent Debt/Assetsof PHAS including historical data for past 10 years.

Interactive Chart of Debt/Assets of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Debt/Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 11.17% 12.59%
2020 28.07% 26.76% 23.98% 19.18% 28.07%
2019 17.82% 11.29% 9.95% 12.88% 19.97%
2018 11.9% 27.28% 0.0% 0.0% 11.9%
2017 0.0% 0.0% 109.8%
2016 0.0%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.